Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 6/20 | 0.38 |
| ▸ | DHODH | Q02127 | 3/20 | 0.35 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.35 |
| ▸ | SCN10A | Q9Y5Y9 | 3/20 | 0.34 |
| ▸ | CBFB | Q13951 | 1/20 | 0.34 |
| ▸ | MLKL | Q8NB16 | 1/20 | 0.33 |
| ▸ | PARP1 | P09874 | 1/20 | 0.33 |
| ▸ | HCRTR1 | O43613 | 2/20 | 0.32 |
| ▸ | HCRTR2 | O43614 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12066027 | 0.84 | RHEB (0.35) | PDE2ASCN10A | |
| SCHEMBL12065657 | 0.83 | MLKL (0.51) | SCN10AMLKL | |
| SCHEMBL14763552 | 0.81 | SCN10A (0.43) | PDE2ASCN10ACBFBMLKL | |
| SCHEMBL12066588 | 0.81 | MLKL (0.40) | PDE2ADHODHTRPV4SCN10ACBFB | |
| SCHEMBL12066025 | 0.79 | SCN10A (0.45) | PDE2ASCN10ACBFBMLKL | |
| SCHEMBL12065255 | 0.78 | SCN10A (0.40) | PDE2ATRPV4SCN10AMLKL | |
| SCHEMBL12066024 | 0.77 | SCN10A (0.36) | PDE2ASCN10A | |
| SCHEMBL12065637 | 0.77 | MLKL (0.49) | SCN10AMLKL | |
| SCHEMBL14762773 | 0.76 | SCN10A (0.43) | PDE2ASCN10AMLKL | |
| SCHEMBL12066550 | 0.76 | MLKL (0.43) | PDE2ASCN10AMLKL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130065896-A1 | FUSED IMIDAZOLE DERIVATIVE | TOA EIYO LTD. (JP) | 2013-03-14 | — | — | US | claimed |
| US-9096531-B2 | Fused imidazole derivative | TOA EIYO LTD. (JP) | 2015-08-04 | — | — | US | disclosed |
| US-20130065896-A1 | FUSED IMIDAZOLE DERIVATIVE | TOA EIYO LTD. (JP) | 2013-03-14 | — | — | US | disclosed |
| WO-2011148956-A1 | FUSED IMIDAZOLE DERIVATIVE | トーアエイヨー株式会社 (JP) | 2011-12-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130065896-A1 | FUSED IMIDAZOLE DERIVATIVE | CACNA1E, CACNA1G, CACNA1A | PDE2A 1306/4885DHODH 2727/4885TRPV4 24/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.